At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treat...
Ardelyx is focused on enhancing the way people ...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...
Infinity Pharmaceuticals, Inc. is an innovative...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Join the National Investor Network and get the latest information with your interests in mind.